David A. Siegel Adagio Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 304,200 shares of ADGI stock, worth $1.01 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
304,200
Previous 22,100
1276.47%
Holding current value
$1.01 Million
Previous $73,000
1278.08%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ADGI
# of Institutions
76Shares Held
70.5MCall Options Held
3.6KPut Options Held
2.1K-
Lee Ainslie Maverick Capital LTD | Dallas, Tx11.8MShares$38.9 Million0.75% of portfolio
-
Mithril Ii Gp LP Austin, TX11.2MShares$37.2 Million30.95% of portfolio
-
Deep Track Capital, LP Greenwich, CT10.7MShares$35.4 Million1.56% of portfolio
-
M28 Capital Management LP Stamford, CT9.25MShares$30.6 Million24.88% of portfolio
-
Black Rock Inc. New York, NY4.47MShares$14.8 Million0.0% of portfolio
About Adagio Therapeutics, Inc.
- Ticker ADGI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 108,831,000
- Market Cap $505M
- Description
- Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...